The RAF proteins are cytosolic protein kinases that regulate cell responses to extracellular signals. There are three RAF proteins in cells, ARAF, BRAF and CRAF, and recent studies have shown that the formation of complexes by these different isoforms has an important role in their activation, particularly in response to RAF inhibitors. Here, we investigated the role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors. We show that two mutations that occur in ARAF in cancer inactivate the kinase. We also show that ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS. We further show that ARAF binds to and is activated by BRAF and that ARAF also forms complexes with CRAF. Critically, ARAF seems to stabilize BRAF:CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency.
INTRODUCTION
The RAF proteins are serine-threonine-specific protein kinases that activate the MEK/ERK cascade downstream of RAS. In normal cells, this pathway is activated by extracellular signals and controls proliferation, survival, senescence and differentiation, whereas in cancer, it is constitutively activated, so proliferation and survival are the favored outcomes. There are three RAF genes in humans, namely, ARAF, BRAF and CRAF, and although BRAF is mutated in B7% of cancers, ARAF and CRAF mutations are rare. 1, 2 This is due to a fundamental difference in RAF isoform regulation mediated by a motif called the N-region. ARAF and CRAF require phosphorylation of conserved serines and tyrosines in the N-region for activation, whereas in BRAF, the serine is constitutively phosphorylated and the tyrosine is substituted with an aspartic acid. Thus BRAF, unlike ARAF or CRAF, is primed for activation and can be converted into an active oncogene by single-point mutations. 3 The most common mutation in BRAF in cancer is substitution of valine 600 (V600) for glutamic acid. 2,4 V600E BRAF has elevated kinase activity and is a confirmed driver oncogene in cancer. Importantly, BRAF inhibitors, such as vemurafenib, mediate impressive clinical responses in melanoma patients whose tumors express V600E BRAF. [5] [6] [7] Over 100 mutations have been described in BRAF in cancer, the majority of which possess elevated kinase activity. However, some, such as G596R BRAF, have impaired kinase activity and cannot phosphorylate MEK directly. 8 Nevertheless they still activate the pathway because they bind to and activate CRAF in a RAS-independent manner. 9, 10 Furthermore, it is CRAF and not BRAF that transmits signals from oncogenic RAS to MEK. [11] [12] [13] Thus, although CRAF mutations are rare in human cancer, CRAF does signal in some contexts and is a validated therapeutic target.
Recent studies have identified a paradox with RAF inhibitors, because although they inhibit the MEK/ERK pathway in cells expressing V600E BRAF, they activate the pathway in cells expressing oncogenic RAS. [14] [15] [16] This is because RAF inhibitors drive RAF dimerization, leading to the formation of BRAF:CRAF heterodimers and CRAF:CRAF homodimers containing a drug-bound and a drug-free partner. Critically, the drug-bound partner activates the drug-free partner through scaffold functions or by inducing a conformational change. These studies reveal the importance of RAF interactions in MEK/ ERK pathway activation, but, although the importance of BRAF:CRAF heterodimers and CRAF:CRAF homodimers have been explored in some depth, the role of ARAF in these processes is less well understood. We therefore studied the role of ARAF in cancer cell signaling and ARAF function in paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors.
RESULTS AND DISCUSSION
To explore ARAF signaling in tumorigenesis, we first characterized two ARAF mutants identified in human cancer. G331C ARAF was identified in a colon carcinoma and A451T ARAF in Molt-4 lymphoblastic leukemia cells. 17, 18 We previously demonstrated that ARAF could be activated by G12V HRAS and Y527F SRC, 19 but show here that G331C ARAF and A451T ARAF were not activated by these oncogenes ( Figure 1a ). Next, we tested whether ARAF, like CRAF, 9 could be activated by G596R BRAF. G596R BRAF stimulated robust activation of ARAF but did not activate G331C ARAF or A451T ARAF ( Figure 1b) . We confirmed that the activity measured in these experiments was of ARAF, because we did not detect RAF activity when using kinase-dead forms of ARAF (Supplementary Figure S1a) .
The inactivation of ARAF by G331C and A451T was unexpected. G331 is between the glycine-rich loop and catalytic lysine of the kinase domain and A451 is adjacent to T452, a conserved activation segment phosphorylation site. 20, 21 These residues are conserved in BRAF and CRAF and the crystal structure of BRAF did not reveal why these substitutions would be inactivating (Supplementary Figure S1b) ARAF (A451T) or G12V HRAS (RAS) was performed as previously described. 3 Error bars represent s.e. from the means. (f ) Whole cell lysates (30 mg) were prepared in NP40 buffer as described 9 and western blotted for CRAF (610152; BD Transduction Laboratories, San Jose, CA, USA), ARAF (C-20; Santa Cruz Biotechnology, Heidelberg, Germany), phospho-ERK (ppERK; M8159; Sigma-Aldrich, St Louis, MO, USA) and total ERK2 (C-14; Santa Cruz) in D04 cells treated with scrambled control (Scr) or CRAF siRNA and co-transfected with empty vector control (EV), ARAF, and A598T BRAF were also inactive (Figure 1c ), but unlike G596R BRAF, they did not activate ARAF ( Figure 1d ). Figure 1f) . Previously, 11 we demonstrated that CRAF depletion by RNA interference suppressed ERK activity in RAS mutant cells and show here that ARAF, G331C ARAF and A451T ARAF overexpression did not rescue ERK activity when CRAF was depleted ( Figure 1f) . As a control, we also tested whether an activated version of ARAF could rescue ERK activity in these cells. For this, we generated E439K ARAF, the ARAF equivalent of E478K CRAF and E586K BRAF, both of which show elevated kinase activity. 2, 3, 9 We verified that E439K ARAF was strongly activated by G12V HRAS and Y527F SRC and by G596R BRAF (Figure 1g ). Nevertheless, E439K ARAF only partially rescued ERK activity in CRAFdepleted D04 cells (Figure 1f ).
The data above show that G331C ARAF and
A451T
ARAF lacked enzymatic and biological activity. A451 is in the activation segment, adjacent to the phosphorylation site at T452 21 and notably, the corresponding region in BRAF is a hotspot for mutations that activate BRAF. 22 It was therefore surprising that the A451T substitution was not activating, but others have suggested that introduction of a hydroxyl group into this region in BRAF would stabilize the inactive conformation of the protein by altering local electrostatic interactions. 23 Accordingly, we confirmed here that A598T BRAF lacked kinase activity. G331 is also in the kinase domain and again the BRAF equivalent ( G478C BRAF) was inactive. It is unclear why this mutant lacked activity, but our preliminary data show that A451T ARAF and G331C ARAF do not bind to BRAF (data not shown), providing a possible explanation for their lack of activity. ARAF mutations are rare in cancer and our data reveals that they show an unexpected lack of activity, suggesting they are either passenger mutations or that their oncogenic activity is only revealed in specific signaling contexts. We also show that ARAF cannot substitute for CRAF, suggesting that they perform distinct functions in RAS mutant cells. We previously reported that BRAF binds to and activates CRAF, 9 so tested whether BRAF also bound to ARAF. Myc-tagged ARAF and HA-tagged BRAF were expressed in COS7 cells and ARAF was immunoprecipitated and probed for BRAF by western blot. We show that BRAF bound to ARAF weakly, but that this binding was substantially increased by G12V HRAS (Figure 2a) . Notably, V600E BRAF and G596R BRAF bound to ARAF robustly, even in the absence of oncogenic RAS (Figure 2a) . We confirmed these findings by immunoprecipitating HA-BRAF and showing that myc-ARAF was bound to it ( Figure 2a ).
Next, we tested whether endogenous ARAF bound to endogenous BRAF. We observed a protein of B90kDa that bound to ARAF in WM266.4 melanoma ( V600D BRAF) and HCT116 colorectal cancer ( G13D KRAS) cells, but was lost when the cells were treated with BRAF targeting small-interfering RNA (siRNA) probes (Figure 2b) . Similarly, we observed a protein of B70kDa that bound to BRAF, but was lost when ARAF was depleted by siRNA ( Figure 2c ). These data confirmed that endogenous BRAF and ARAF bound to each other in BRAF and RAS mutant cells. We previously demonstrated that RAS recruited BRAF and CRAF to the plasma membrane, 19 so tested whether RAS also recruits ARAF to the membrane. We confirmed that ARAF was cytosolic in the absence of oncogenic RAS, but membrane bound in its presence (Figure 2d ). In contrast, ARAF remained cytosolic in the 
HRAS (RAS).
The spaces indicate discontinuous sections of the same gel. Cell fractionation assays were as described. 10 presence of G596R BRAF (Figure 2d) . Thus, ARAF bound to WT BRAF at the plasma membrane in a RAS-dependent manner, but bound to and was activated by cytosolic G596R BRAF in a RAS-independent manner. We conclude that like CRAF, ARAF is a BRAF effector protein.
Recent studies have shown that RAF inhibitors drive CRAF binding to BRAF,
14,15 so we tested whether they also drove ARAF binding to BRAF and/or CRAF. We treated D04 cells with the BRAF selective inhibitor SB590885 and the pan-RAF inhibitor sorafenib, immunoprecipitated endogenous ARAF and probed for BRAF. We observed that ARAF formed a constitutive complex with BRAF in D04 cells (Figure 3a ), but that this interaction was further enhanced by RAF inhibitors in a dose-dependent manner, confirming previous findings. 15 Note that ARAF binding to BRAF was constitutive in BRAF mutant A375P and WM266.4 melanoma cells and was not enhanced by sorafenib, SB590885 or PD184352 (Supplementary Figure S2a) , confirming that these drugs did not increase ARAF binding to mutant BRAF.
We previously demonstrated that BRAF:CRAF dimerization required both BRAF and CRAF binding to RAS, 14 so tested whether ARAF binding to RAS was also required. We generated an ARAF mutant ( R52L ARAF) that cannot bind to RAS and found that this mutant still bound to BRAF in the presence of oncogenic RAS (Figure 3b) . Notably however, the corresponding RAS-binding-deficient BRAF mutant ( R188L BRAF) did not bind to ARAF, showing that the BRAF:ARAF interaction required only BRAF to bind to RAS (Figure 3b) . These results were corroborated by kinase assays where we show that ARAF activation by BRAF required BRAF binding to RAS, but not ARAF binding to RAS (Figure 3c) .
While performing these studies, we observed that ARAF also bound to CRAF (Figure 3a ). Sorafenib and, albeit less efficiently, SB590885 induced ARAF binding to CRAF. However, in contrast to ARAF binding to BRAF, ARAF binding to CRAF in untreated cells was variable and, in general, ARAF did not bind to CRAF in untreated cells (Figure 3d ), although weak binding was occasionally seen (Figure 3a) . We concluded that ARAF binding to CRAF was less robust that ARAF binding to BRAF, and in agreement with previous data showing that ERK destabilized RAF dimers by feedback phosphorylation, 24 we confirmed that the MEK inhibitor PD184352 stabilized ARAF:CRAF complexes in SB590885-treated cells (Figure 3d ). Next, we examined whether ARAF was activated by druginduced RAF dimerization. SB590885 activated ARAF robustly in D04 cells (Figure 3e ), albeit less efficiently than it activated CRAF (Supplementary Figure S2b) . To confirm the activation of ARAF by SB590885, we expressed kinase-dead forms of ARAF in Araf null mouse embryonic fibroblasts (MEFs) and showed that these mutants were not activated (Figure 3f, Supplementary Figure S2c) . Critically, ARAF activation was impaired in Braf null MEFs (Supplementary Figure S2d) , but recovered when BRAF was re-expressed in these cells (Figure 3g; Supplementary Figure S2e) . Note, when T529N BRAF, a BRAF mutant that does not bind to SB590885, was expressed in Braf null cells, ARAF was not activated (Figure 3g ). This demonstrates that it is binding of the drugs to BRAF rather than ARAF that drives ARAF activation. Finally, we did not observe ARAF activation by SB590885 in BRAF mutant WM266.4 cells (Figure 3e ).
Our data confirmed that RAF inhibitors activated ARAF but also demonstrated that ARAF and CRAF bound to BRAF with different characteristics. Specifically, whereas CRAF binding to BRAF required CRAF binding to RAS, 14 ARAF did not need to bind to RAS to bind to BRAF or be activated. Moreover, although RAF inhibitors increased ARAF and CRAF binding to BRAF, ARAF bound to BRAF weakly even in untreated cells whereas CRAF did not. Thus, ARAF and CRAF seem to be paradoxically activated by distinct mechanisms. Figure S3a) , and ARAF depletion did not suppress MEK/ERK signaling in BRAF mutant cells (Supplementary Figure S3b) . As already shown (Figure 1f) , CRAF depletion suppressed MEK/ERK activity in D04 cells (Figure 4a) . Critically, and despite not affecting ERK activity alone, ARAF depletion cooperated with CRAF depletion to further inhibit MEK/ ERK activity (Figure 4a ). These data confirmed that ARAF and CRAF have distinct roles in MEK/ERK signaling in RAS mutant cells. Importantly, when ARAF was depleted in DO4 cells, we observed a strong reduction in CRAF binding to BRAF (Figure 4b ), suggesting that ARAF stabilized BRAF binding to CRAF. Surprisingly, the destabilization of the BRAF:CRAF complex in ARAF-depleted cells did not reduce paradoxical activation of MEK and ERK in SB590885-treated cells (Figure 4b) . However, paradoxical activation of MEK and ERK can be mediated by CRAF:CRAF homodimers, 16 Although signaling can be rewired amongst RAF isoforms in drug-resistant BRAF mutant cells, 25 we show here that ARAF and CRAF cannot compensate for each other in a RAS mutant background, and therefore perform distinct functions. We also show that ARAF is a BRAF effector protein that was activated by wild-type BRAF in a RAS-dependent manner, but was activated by mutant BRAF in a RAS-independent manner. Notably, however, we demonstrated that unlike CRAF, ARAF did not need to bind to RAS to bind to wild-type BRAF. We further demonstrated that in some cells ARAF stabilized CRAF binding to BRAF, but our preliminary data suggests that ARAF was not essential for CRAF binding to BRAF in all cells, possibly because other proteins, including the kinase suppressor of RAS (KSR) can also perform this function and so mask the contribution from ARAF. Indeed, the scaffold function of proteins such as ARAF and KSR may be highly complex; in some cells KSR was reported to enhance CRAF activation by RAF inhibitors, 26 whereas in other cells KSR was reported to antagonize CRAF activation. 27 Recent studies have established an unexpected complexity in RAF signaling that makes it difficult to assign specific functions to individual RAF isoforms and, accordingly, we show that the contribution of ARAF to RAS signaling was only apparent when CRAF was depleted. Nevertheless, we confirm that ARAF is a BRAF effector protein that is paradoxically activated by RAF inhibitors and we reveal an additional level of complexity by showing that, in some cells, ARAF stabilizes BRAF:CRAF complexes to sustain signaling efficiency.
